FTFinancial Times·2hBusiness
score-0.30
Melanoma Vaccine Cuts Recurrence Risk by 58% as Moderna Shares Dip on Market Expectations
Original
Moderna shares sink after leaked cancer data missed expectations
“Contrasts significant medical efficacy (58% risk reduction) with negative market reaction to missed financial expectations.”